|
|
|
08.06.26 - 22:06
|
City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics (Business Wire)
|
|
|
Viking Global Investors and Sofinnova Investments join a strong syndicate of existing investors including ARCH Venture Partners, Fidelity Management & Research Company and Invus
Proceeds to accelerate the company's RNAi engineering platform and pipeline, including ongoing Phase 1 clinical trial of CITY-FXI and two additional programs progressing into the clinic by year-end 2026CAMBRIDGE, Mass.--(BUSINESS WIRE)--City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced the completion of a $99.5 million Series B financing. Viking Global Investors and Sofinnova Investments participated in the financing as new investors, along with Casdin Capital and NYBC Ventures, joined by existing investors ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures and other undisclosed investors.
Proceeds will be used to advance City Therapeutics' pipeline of RNAi ...
|
|
|
|
|
|
|
|
|
04.06.26 - 12:00
|
Regeneron and CytomX extend cancer therapy partnership to $4bn deal (PBR)
|
|
|
The collaboration combines CytomX's Probody technology with Regeneron's Veloci‑Bi bispecific platform to target hard‑to‑treat tumour types. Established in 2022, the partnership combines CytomX's biologic masking technology with Regeneron's
The post Regeneron and CytomX extend cancer therapy partnership to $4bn deal appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.05.26 - 13:03
|
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss (GlobeNewswire EN)
|
|
|
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU)....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
